Clinical trials: SAR
Seasonal Allergic Rhinitis
Efficacy and Safety of Ciclesonide Nasal Spray in Participants With Seasonal Allergic Rhinitis (SAR) in Russia
The purpose of this study is to explore the efficacy and safety of Ciclesonide Nasal Spray 200 microgram (mcg) once daily in the treatment of seasonal allergic rhinitis (SAR) in Russian participants.
- Trial name
- NCT02155881
- Testing
- Ciclesonide
- Where
- 5 sites in Russia
- Volunteers
- 80 people
- Sponsor
- AstraZeneca
Dry Eye
A Study Evaluating the Efficacy of SAR 1118 (0.1%, 1.0%, 5.0%) Ophthalmic Solution in Subjects With Dry Eye Conducted in a Controlled Adverse Environment (CAE)
The purpose of this study is to evaluate the efficacy of three different concentrations (0.1%, 1.0%, 5.0%) of SAR 1118 Ophthalmic Solution compared to placebo in the treatment of dry eye.
- Trial name
- NCT00926185
- Testing
- Lifitegrast
- Where
- 5 sites in United States
- Volunteers
- 230 people
- Sponsor
- Shire
Rhinitis, Allergic, Seasonal, Hay Fever
Study Using the Environmental Exposure Chamber (EEC) to Assess the Onset of Action of Ciclesonide, Applied as a Nasal Spray in Treatment of Seasonal Allergic Rhinitis (BY9010/M1-406)
The primary objective of this placebo-controlled EEC study is to determine the time to onset of action of ciclesonide, applied as a nasal spray (200 mg, once daily) in patients with SAR.
- Trial name
- NCT00659594
- Testing
- Ciclesonide
- Where
- Canada
- Volunteers
- 500 people
- Sponsor
- AstraZeneca
Rhinitis, Allergic, Seasonal, Hay Fever
Study Using the Environmental Exposure Unit (EEU) to Assess the Onset of Action of Ciclesonide, Applied as a Nasal Spray in the Treatment of Seasonal Allergic Rhinitis (BY9010/M1-407)
The primary objective of this placebo-controlled EEU study is to determine the time to onset of action of ciclesonide, applied as a nasal spray (200 mg, once daily) in patients with SAR.
- Trial name
- NCT00659503
- Testing
- Ciclesonide
- Where
- Canada
- Volunteers
- 420 people
- Sponsor
- AstraZeneca
Rhinitis, Allergic, Seasonal, Seasonal Allergic Rhinitis
Trial With Rhinitic Patients Taking GSK256066 Versus Placebo In A Pollen Challenge Chamber
This study is in patients with seasonal allergic rhinitis(SAR)and will compare the effect versus placebo of repeat doses of intranasal GSK256066 using the Vienna Challenge Chamber.
- Trial name
- NCT00377728
- Testing
- GSK256066
- Where
- Austria
- Volunteers
- 44 people
- Sponsor
- GlaxoSmithKline
Seasonal Allergic Rhinitis
A Study to Assess the Efficacy and Safety of PG-011 Nasal Spray in Adults With Moderate to Severe Seasonal Allergic Rhinitis
The study is a multicenter, randomized, double-blind, placebo-controlled seamless and adaptive-designed phase IIb/III study encompassing a phase IIb and a phase III component.
- Trial name
- Pumecitinib (NCT06837233)
- Testing
- Pumecitinib Nasal Spray 0.3%, Pumecitinib Nasal Spray 0.6%, Pumecitinib nasal spray 0.6%(twice daily)
- Where
- 20 sites in China
- Volunteers
- 179 people
- Sponsor
- Prime Gene Therapeutics Co., Ltd.
Seasonal Allergic Rhinitis
This Study Contains an Active Drug Treatment Group With Mometasone Furoate Nasal Spray and a Placebo (Dummy) Treatment Group for Seasonal Allergic Rhinitis (SAR). (Study P05073)(COMPLETED)
The purpose of this study is to evaluate how well mometasone furoate nasal spray (MFNS) works to relieve SAR symptoms compared to Placebo when symptoms are induced in a chamber setting.
- Trial name
- NCT00491504
- Testing
- Mometasone Furoate Nasal Spray
- Volunteers
- 310 people
- Sponsor
- Organon and Co
Prostate Cancer, Prostate Cancer Patients With Detectable PSA Following Prostatectomy
64Cu-SAR-bisPSMA Positron Emission Tomography: A Phase 3 Study of Participants With Biochemical Recurrence of Prostate Cancer
The aim for this study is to investigate the ability of 64Cu-SAR-bisPSMA PET/CT to detect recurrence of prostate cancer
- Conditions
- Prostate Cancer, Prostate Cancer Patients With Detectable PSA Following Prostatectomy, Prostate Cancer Recurrent, Prostate Cancer Patients Who Have Brachytherapy Seed Implant
- Trial name
- AMPLIFY (NCT06970847)
- Testing
- 64Cu-SAR-bisPSMA
- Where
- 22 sites in United States, Australia
- Volunteers
- 220 people
- Sponsor
- Clarity Pharmaceuticals Ltd